Hanmi Pharm’s innovative anticancer drug ‘Posiotinib’ published in international SCI journal

Published: 2018-04-25 16:40:37

Updated: 2018-04-25 16:40:37

A research result of Poziotinib, a targeted therapy for cancer developed by Hanmi Pharm, was registered in the online version of Nature Medicine, an international SCI(Science Citation Index) journal.

Spectrum Pharmaceuticals, a U.S. partner of Hanmi Pharm(CEO Sae-Chang Kwon & Jong-Soo Woo), announced this in a press release on the 23^rd(local time), and mentioned possibilities to smoothly devel...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.